COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients.
COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients.
复制标题
DOI：
10.1038/s41598-022-16113-6
复制
发表时间：
2022-07-14
影响因子：
4.6
通讯作者：
Muehlschlegel, Jochen D.
中科院分区：
文献类型：
--
作者：
Wollborn, Jakob;Karamnov, Sergey;Fields, Kara G.;Yeh, Tiffany;Muehlschlegel, Jochen D.
COVID-19与显著的肺外症状相关。已描述了SARS-CoV-2感染的心肌受累，这可能导致发病率和死亡率增加。本研究的目的是调查住院患者中COVID-19与心房颤动（AF）或心房扑动（AFl）的相关性。这项回顾性研究使用电子病历来检测马萨诸塞州总布里格姆医院系统内的COVID-19患者及其合并症。对所有住院并接受SARS-CoV-2 PCR检测的≥ 18岁患者以及来自大流行前队列的患者进行了入选筛选。我们匹配了房颤的常见危险因素，然后使用多变量逻辑回归来估计房颤或房颤的几率。在符合分析条件的78，725名患者中，11，004名COVID-19阴性患者与3，090名COVID-19阳性患者匹配，5005名大流行前患者与2283名COVID-19阳性患者匹配。在调整人口统计学和合并症后，与COVID-19阴性患者相比，COVID-19阳性患者发生AF的几率是1.19倍（95%CI 1.00，1.41），与大流行前患者相比，发生AF的几率是1.57倍（95%CI 1.23，2.00）。我们的研究表明，房颤的风险增加，从而将注意力集中在改善COVID-19后遗症的筛查和治疗方案上。虽然COVID-19继续影响世界各地的许多人，但AF可能是发病和死亡的重要原因。房颤的充分检测和治疗对于减轻疾病负担至关重要。
COVID-19 is associated with significant extrapulmonary symptoms. Myocardial involvement has been described for infections with SARS-CoV-2 which may lead to an increase in morbidity and mortality. The objective of our study was to investigate the association of COVID-19 and atrial fibrillation (AF) or atrial flutter (AFl) in hospitalized patients. This retrospective study used electronic medical records to detect patients with COVID-19 and their comorbidities within the Mass General Brigham hospital system. All patients ≥ 18 years who were hospitalized and received a PCR test for SARS-CoV-2 were screened for inclusion as well as patients from a pre-pandemic cohort. We matched on common risk factors for AF and then used multivariable logistic regression to estimate the odds for AF or AFl. Of 78,725 patients eligible for analysis, 11,004 COVID-19 negative patients were matched to 3,090 COVID-19 positive patients and 5005 pre-pandemic patients were matched to 2283 COVID-19 positive patients. After adjusting for demographics and comorbidities, COVID-19 positive patients had 1.19 times the odds (95% CI 1.00, 1.41) of developing AF compared to COVID-19 negative patients and 1.57 times the odds (95% CI 1.23, 2.00) of developing AF compared to pre-pandemic patients. Our study demonstrated an increased risk for AF, directing the attention for improved screening and treatment regimens for the sequelae of COVID-19. While COVID-19 continues to affect many people around the world, AF may be a significant cause for morbidity and mortality. Adequate detection and treatment of AF is essential to reduce the burden of disease.
登录
查看更多内容
影响因子：
1.1
作者：
Philips CA;Mohan N;Ahamed R;Kumbar S;Rajesh S;George T;Mohanan M;Augustine P
通讯作者：
Augustine P
影响因子：
15.3
作者：
Vandenbroucke, Jan P.;von Elm, Erik;Egger, Matthias
通讯作者：
Egger, Matthias
影响因子：
24
作者：
Puntmann, Valentina O.;Carerj, M. Ludovica;Nagel, Eike
通讯作者：
Nagel, Eike
影响因子：
3.7
作者：
Ambrus DB;Benjamin EJ;Bajwa EK;Hibbert KA;Walkey AJ
通讯作者：
Walkey AJ
DOI：
10.1111/jth.14817
发表时间：
2020-05
期刊：
Journal of thrombosis and haemostasis : JTH
影响因子：
--
作者：
通讯作者：
--